Who Paid My Doc
Mohammad Jafferany
Child & Adolescent Psychiatry Saginaw, MI Medical Doctor
NPI 1811008139 CMS profile 128003
3201 Hallmark Ct, Saginaw, MI 48603
General payments
$10,012
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$7,000
Through program year 2025, Mohammad Jafferany of Saginaw, MI is reported in the CMS Open Payments database as having received $10,012 across 186 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $7,000 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 96th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $4,887 | 2 | |
| 2023 | General | $15 | 1 | |
| 2022 | General | $15 | 1 | |
| 2021 | General | $925 | 57 | |
| 2020 | General | $915 | 50 | |
| 2019 | General | $3,255 | 75 |
Beside peers
- Mohammad Jafferany
- Child & Adolescent Psychiatry median
- Middle half of Child & Adolescent Psychiatry
- National median
In program year 2025, general payments to Mohammad Jafferany were reported at $4,887. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.
Show as a table
| Year | Mohammad Jafferany | Child & Adolescent Psychiatry median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $3,255 | $129 | $42–$419 | $163 |
| 2020 | $915 | $81 | $28–$226 | $114 |
| 2021 | $925 | $115 | $31–$326 | $132 |
| 2022 | $15 | $124 | $40–$382 | $149 |
| 2023 | $15 | $130 | $45–$420 | $160 |
| 2024 | $0 | $141 | $42–$490 | $164 |
| 2025 | $4,887 | $132 | $41–$474 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 20 drugsPart D claims
613
Drug cost
$20,099
Branded share of claims
16.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Risperdal Consta Risperidone Microspheres | Brand | 17 | $10,825 | |
| Aripiprazole | Generic | 48 | $2,241 | |
| Buspirone Hcl | Generic | 70 | $885 | |
| Oxcarbazepine | Generic | 14 | $881 | |
| Lamotrigine | Generic | 46 | $814 | |
| Bupropion Xl Bupropion Hcl | Brand | 30 | $664 | |
| Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine | Brand | 23 | $533 | |
| Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine | Brand | 16 | $478 | |
| Duloxetine Hcl | Generic | 21 | $457 | |
| Clonazepam | Generic | 72 | $373 |
The 10 drugs with the highest cost, of 20 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 18 billing codesPaid by Medicare
$21,150
Medicare patients
148
Services billed
315
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 74% | |
| Depression | 74% | |
| Arthritis | 48% | |
| Diabetes | 40% | |
| Chronic kidney disease | 33% | |
| Alzheimer's or dementia | 28% | |
| Ischemic heart disease | 22% | |
| COPD | 22% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
186 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Child & Adolescent Psychiatry in Michigan
Birgit Amann
Child & Adolescent Psychiatry · Troy, MI
David Villanueva
Child & Adolescent Psychiatry · Sterling Heights, MI
Carol Crouch-Ross
Child & Adolescent Psychiatry · Livonia, MI
Robert Garcia
Child & Adolescent Psychiatry · Northville, MI
Gerald Schmuker
Child & Adolescent Psychiatry · Spring Lake, MI
Sridevi Kodali
Child & Adolescent Psychiatry · Livonia, MI
Related records
Child & Adolescent Psychiatry in Michigan
Practitioners in the same specialty and state, ranked by reported value.
All Child & Adolescent Psychiatry
Everyone recorded under this specialty, nationwide.
Doctors in Michigan
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.